Abstract
The human multidrug transporter MDR1 P-glycoprotein and the multidrug resistance proteins MRP1 and MRP2 transport a range of cytotoxic drugs, resulting in multidrug resistance in tumour cells. To overcome this form of drug resistance in patients, several inhibitors (reversal agents) of these transporters have been isolated. Using polarized cell lines stably expressing human MDR1, MRP1 or MRP2 cDNA, and 2008 ovarian carcinoma cells stably expressing MRP1 cDNA, we have investigated in this study the specificity of the reversal agents V-104 (a pipecolinate derivative), GF120918 (an acridone carboxamide derivative also known as GG918), and Pluronic L61 (a (poly)oxypropethylene and (poly)oxypropylene block copolymer). Transport experiments with cytotoxic drugs with polarized cell lines indicate that all three compounds efficiently inhibit MDR1 Pgp. Furthermore, V-104 partially inhibits daunorubicin transport by MRP1 but not vinblastine transport by MRP2. V-104 reverses etoposide resistance of 2008/MRP1 cells, whereas GF120918 does not reverse resistance due to MRP1. V-104 partially inhibits the export of the organic anion dinitrophenyl S -glutathione by MDCKII-MRP1 but not by MDCKII-MRP2 cells. Unexpectedly, export of the organic anion calcein by MDCKII-MRP1 and MDCKII-MRP2 cells is stimulated by Pluronic L61, probably because it relieves the block on entry of calcein AM into the cell by endogenous MDR1 Pgp. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Bakos E, Evers R, Szakacs G, Tusnad GE, Welker E, Szabo K, de Haas M, van Deemter L, Borst P, Varadi A and Sarkadi B (1998) Functional multidrug resistance protein (MRP1) lacking the N-terminal transmembrane domain. J Biol Chem 273: 32167–32175
Batrakova EV, Han HY, Miller DW and Kabanov AV (1998) Effects of pluronic P85 unimers and micelles on drug permeability in polarized BBMEC and Caco-2 cells. Pharm Res 15: 1525–1532
Batrakova EV, Dorodnych TY, Klinskii EY, Kliushnenkova EN, Hemchukova OB, Goncharova ON, Arjakov SA, Alakhov VY and Kabanov AV (1996) Anthracycline antibiotics non-covalently incorporated into the block copolymer micelles: in vivo evaluation of anti-cancer activity. Br J Cancer 74: 1545–1552
Böhme M, Büchler M, Müller M and Keppler D (1993) Differential inhibition of cyclosporins of primary-active ATP-dependent transporters in the hepatocyte canalicular membrane. FEBS Lett 333: 193–196
Chen ZS, Kawabe T, Ono M, Aoki S, Sumizawa T, Furukawa T, Uchiumi T, Wada M, Kuwano M and Akiyama SI (1999) Effect of multidrug resistance-reversing agents on transporting activity of human canalicular multispecific organic anion transporter. Mol Pharmacol 56: 1219–1228
Cole SPC and Deeley RG (1998) Multidrug resistance mediated by the ATP-binding cassette transporter protein MRP. Bioassays 20: 931–940
Cole SPC, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AMV and Deeley RG (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258: 1650–1654
Cui Y, König J, Buchholz U, Spring H, Leier I and Keppler D (1999) Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol Pharmacol 55: 929–937
Evers R, Cnubben WHP, Wijnholds J, van Deemter C, van Bladeren P and Borst P (1997) Transport of glutathione prostaglandin A conjugates by the multidrug resistance protein 1. FEBS Lett 419: 112–116
Evers R, de Haas M, Sparidans R, Beijnen J, Wielinga PR, Lankelma L and Borst P (2000) Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. Br J Cancer 83: 375–383
Evers R, Zaman GJR, van Deemter L, Jansen H, Calafat J, Oomen LCJM, Oude Elferink RPJ, Borst P and Schinkel AH (1996) Basolateral localization and export activity of the human multidrug resistance-associated protein in polarized pig kidney cells. J Clin Invest 97: 1211–1218
Evers R, Kool M, van Deemeter L, Janssen H, Calafat J, Oomen LCJM, Paulusma CC, Oude Elferink RPJ, Baas F, Schinkel AH and Borst P (1998) Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA. J Clin Invest 101: 1310–1319
Feller N, Broxterman HJ, Wähler DCR and Pinedo HM (1995) ATP-dependent efflux of calcein by the multidrug resistance protein (MRP): no inhibition by intracellular glutathione depletion. FEBS Lett 368: 385–388
Fisher GA and Sikic BI (1995) Clinical studies with modulators of multidrug resistance. Hematol Oncol Clin North Am 9: 363–382
Germann UA, Shlyakhter D, Mason VS, Zelle RE, Duffy JP, Galullo V, Armistead DM, Saunders JO, Boger J and Harding MW (1997a) Cellular and biochemical characterization of VX-710 as a chemosensitizer: reversal of P-glycoprotein-mediated multidrug resistance in vitro. Anticancer Drugs 8: 125–140
Germann UA, Ford PJ, Shlyakhter D, Mason VS and Harding MW (1997b) Chemosensitization and drug accumulation effects of VX710, verapamil, cyclosporin A, MS209 and GF120918 in multidrug resistant HL60/ADR cells expressing the multidrug resistance-associated protein MRP. Anticancer Drugs 8: 141–155
Gottesmann MM, Hrycyna CA, Schoenlein PV, Germann UA and Pastan I (1995) Genetic analysis of the multidrug transporter. Annu Rev Genet 29: 607–649
Hirohashi T, Suzuki H and Sugiyama Y (1999) Characterization of the transport properties of cloned rat multidrug resistance protein 3 (MRP3). J Biol Chem 274: 15181–15185
Holló Z, Homolya T, Hegedus T and Sarkadi B (1996) Transport properties of the multidrug resistance-associated protein (MRP) in human tumour cells. FEBS Lett 383: 99–104
Homolya L, Holló Z, Müller M, Mechetner EB and Sarkadi B (1996) A new method for a quantitative assessment of P-glycoprotein-related multidrug resistance in tumour cells. Br J Cancer 73: 849–855
Hooijberg JH, Broxterman HJ, Kool M, Assaraf YG, Peters GJ, Noordhuis P, Scheper RJ, Borst P, Pinedo HM and Jansen G (1999) Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res 59: 2532–2535
Hyafil F, Vergely C, Du Vignaud P and Grand-Perret T (1993) In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxymide derivative. Cancer Res 53: 4595–4602
Jedlitschky G, Leier I, Buchholz U, Hummel-Eisenbeiss J, Burchel B and Keppler D (1997) ATP-dependent transport of bilirubin glucuronides by the multidrug resistance protein MRP1 and its hepatocyte canalicular isoform MRP2. Biochem J 327: 305–310
Juliano RL and Ling V (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochem Biophys Acta 455: 152–162
Keppler D, Jedlitschky G and Leier I (1998) Transport function and substrate specificity of multidrug resistance proteins. Methods Enzymol 292: 607–616
Kool M, van der Linden M, de Haas M, Baas F and Borst P (1999a) Expression of human MRP6, a homologue of the multidrug resistance protein gene MRP1, in tissues and cancer cells. Cancer Res 59: 175–182
Kool M, van der Linden M, de Haas M, Scheffer GL, de Vree ML, Smith AJ, Jansen G, Peters GJ, Ponne N, Scheper RJ, Oude Elferink RPJ, Baas F and Borst P (1999b) MRP3, a new organic anion transporter able to transport anti-cancer drugs. Proc Natl Acad Sci USA 96: 6914–6919
Kool M, de Haas M, Scheffer GL, Scheper RJ, van Eijk MJT, Juijn JA, Baas F and Borst P (1997) Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologs of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res 57: 3527–3547
Leier I, Jedlitschky G, Buchholz U, Cole SPC, Deeley RG and Keppler D (1994) The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates. J Biol Chem 269: 27807–27810
Loe DW, Almquist KC, Deeley R and Cole SPC (1996) Multidrug resistance protein (MRP)-mediated transport of leukotriene C4 and chemotherapeutic agents in membrane vesicles. J Biol Chem 271: 9675–9682
Loe DW, Deeley RG and Cole SPC (1998) Characterization of vincristine transport by the M(r) 190 000 multidrug resistance protein (MRP): evidence for cotransport with reduced glutathione. Cancer Res 58: 5130–5136
Masuda M, I'izuka Y, Yamazaki M, Nishigaki R, Kato Y, Ni'inuma K, Suzuki H and Sugiyama Y (1998) Methotrexate is excreted into the bile by canalicular multispecific organic anion transporter in rats. Cancer Res 57: 3506–3510
Miller DW, Batrakova EV and Kabanov AV (1999) Inhibition of multidrug resistance-associated protein (MRP) functional activity with pluronic block copolymers. Pharmaceutical Res 16: 396–401
Miller DW, Batrakova EV, Waltner TO, Alakhov VY and Kabanov AV (1997) Interactions of pluronic block copolymers with brain microvessel endothelial cells: evidence of two potential pathways for drug absorption. Bioconjugate Chem 8: 649–657
Müller M, Meijer C, Zaman GJR, Borst P, Scheper RJ, Mulder NH, de Vries EGE and Janssen PLM (1994) Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S -conjugate transport. Proc Natl Acad Sci USA 91: 8822–8826
Nerurkar MM, Ho NFH, Burton PS, Vidmar TJ and Borchardt RT (1997) Mechanistic roles of neutral surfactants on concurrent polarized and passive membrane transport of a model peptide in Caco-2 cells. J Pharm Sci 86: 813–821
Oude Elferink RPJ, Bakker CTM and Jansen PLM (1993) Glutathione-conjugate transport by human colon adenocarcinoma cells (Caco-2 cells). Biochem J 290: 759–764
Rappa J, Lorico A, Flavell RA and Sartorelli AC (1997) Evidence that the multidrug resistance protein (MRP) functions as a co-transporter of glutathione and natural product toxins. Cancer Res 57: 5232–5237
Rowinsky EK, Smith L, Wang YM, Chaturvedi P, Villalona M, Campbell E, Aylesworth C, Eckhardt SG, Hammond L, Kraynak M, Drengler R, Stephenson J, Harding MW and Von Hoff DD (1998) Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP. J Clin Oncol 16: 2964–2967
Sarkadi B and Müller M (1997) Search for specific inhibitors of multidrug resistance in cancer. Semin Cancer Biol 8: 171–182
Schinkel AH, Wagenaar E, van Deemter L, Mol CAAM and Borst P (1995) Absence of the mdr1a P-glycoprotein in mice affects the tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 96: 1698–1705
Schuetz JD, Conelly MC, Sun D, Paibir SG, Flynn PM, Srinivas RV, Kumar A and Fridland A (1999) MRP4: A previously unidentified factor in resistance to nucleoside based antiviral drugs. Nat Med 5: 1048–1051
Smith AJ, Mayer U, Schinkel AH and Borst P (1998) Availability of PSC833, a substrate and inhibitor of P-glycoprotein, in various concentrations of serum. J Natl Cancer Inst 90: 1161–1166
Szabo K, Welker E, Bakos E, Muller M, Roninson I, Varadi A and Sarkadi B (1998) Drug stimulated nucleotide trapping in the human multidrug transporter MDR1. Cooperation of the nucleotide binding domains. J Biol Chem 273: 10132–10138
Twentyman PR and Bleehen NM (1991) Resistance modification by PSC833, a novel non-immunosuppressive cyclosporin. Eur J Cancer 27: 1639–1642
Venne A, Li S, Mandeville R, Kabanov A and Alakhov V (1996) Hypersensitizing effect of pluronic L61 on cytotoxic activity, transport, and subcellular distribution of doxorubicin in multiple drug-resistant cells. Cancer Res 56: 3626–3629
Wallstab A, Koester M, Böhme M and Keppler D (1999) Selective inhibition of MDR1 P-glycoprotein-mediated transport by the acridone carboxamide derivative GG918. Br J Cancer 79: 1053–1060
Yanagisawa T, Newman A, Coley H, Renshaw J, Pinkerton CR and Pritchard-Jones K (1999) Biricodar (VX-710; Incel): a selective chemosensitizer in neuroblastoma. Br J Cancer 80: 1190–1196
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Evers, R., Kool, M., Smith, A. et al. Inhibitory effect of the reversal agents V-104, GF120918 and Pluronic L61 on MDR1 Pgp-, MRP1- and MRP2-mediated transport. Br J Cancer 83, 366–374 (2000). https://doi.org/10.1054/bjoc.2000.1260
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1260
Keywords
This article is cited by
-
Genotoxicity of pyrrolizidine alkaloids in metabolically inactive human cervical cancer HeLa cells co-cultured with human hepatoma HepG2 cells
Archives of Toxicology (2023)
-
In vitro function and in situ localization of Multidrug Resistance-associated Protein (MRP)1 (ABCC1) suggest a protective role against methyl mercury-induced oxidative stress in the human placenta
Archives of Toxicology (2020)
-
Streptococcus agalactiae disrupts P-glycoprotein function in brain endothelial cells
Fluids and Barriers of the CNS (2019)
-
Identification of novel cell-impermeant fluorescent substrates for testing the function and drug interaction of Organic Anion-Transporting Polypeptides, OATP1B1/1B3 and 2B1
Scientific Reports (2018)
-
pH-sensitive micelles for the intracellular co-delivery of curcumin and Pluronic L61 unimers for synergistic reversal effect of multidrug resistance
Scientific Reports (2017)